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Purpose: The aim of this study was to describe the recent conditions associated with implantable
deﬁbrillation therapy for individual underlying heart diseases.
Methods: Ten thousand six hundred and ﬁve patients with implantable cardioverter-deﬁbrillators (ICDs) or
cardiac resynchronization therapy deﬁbrillators (CRT-Ds) that were implanted from 2006 to 2010 were
selected from the Japan Cardiac Device Therapy Registry database. They were divided into 12 disease
categories and further divided into either primary or secondary prevention of sudden cardiac death.
Results: The major underlying diseases of the patients in this cohort were ischemic heart disease (IHD, 35%),
dilated cardiomyopathy (DCM, 25%), hypertrophic cardiomyopathy (HCM, 8%), and Brugada syndrome
(Brugada, 8%). There were no structural heart diseases in this cohort; the incidence of IHD was relatively
lower than that of western countries, while the incidence of cardiomyopathy was higher. The percentage of
primary prevention (% primary) among the individual diseases varied. IHD was the most prevalent
underlying condition in the patient cohort; however, the % primary was 33%, which was relatively lower
than that of the other structural heart diseases. The % primary was relatively higher in patients with DCM
(57%) and Brugada (47%). Over 5 years, the % primary gradually increased in patients with DCM, IHD, and
HCM, with a particularly dramatic increase in those with DCM. A decrease in the % primary among patients
with Brugada began in 2008.
Conclusions: In patients that underwent implantable deﬁbrillation therapy, there was a relatively lower %
primary in the IHD group, and a substantial increase in the % primary in patients with DCM.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Implantable cardioverter-deﬁbrillators (ICD), cardiac resyn-
chronization therapy deﬁbrillators (CRT-D), and cardiac resyn-
chronization therapy (CRT-P) are useful tools for improving the
prognosis and/or sudden cardiac death event rate in patients with
heart failure and/or fatal ventricular arrhythmias [ventricular
tachycardia (VT) and ventricular ﬁbrillation (VF)] [1–9]. The ICD
implantation rate increased signiﬁcantly worldwide [10–12] fol-
lowing controlled studies of primary and secondary prevention of
cardiac death [13–19]. New guidelines for ICD implantation [12]
and the progressive technological advances in implantable
devices have also contributed to this ongoing increasing trend.
In Japan, the ﬁrst guidelines for ICDs were published by the
Japanese Circulation Society (JCS) in 2001 [20], a revised version
was reported in its website in 2006 [21], and a further revised
version was added in 2011 [22]. CRT-Ds were approved in 2006rt Rhythm Society. Published by E
Committee of the Japanese
.
Shimizu).and the Japan Cardiac Device Therapy Registry (JCDTR) was
started in the same year [23]. Interestingly, it has been reported
that the actual implantation rates of these devices in Japan may
be different from those of western countries [25]. These differ-
ences in device utilization rates might be explained by variable
factors such as acceptance of published guidelines, differences in
clinical presentation of patients, access to electrophysiologists
and other implantation specialists, the overall capacity of the
workforce to support ICD implantation, acceptance by policy-
makers, cost-effectiveness, ﬁnancial constraints, and capitation
[23]. However, little is known regarding the recent conditions
associated with implantable deﬁbrillators for the treatment of
individual underlying heart diseases. Therefore, we investigated
the actual conditions associated with implantable deﬁbrillation
therapy over a 5-year period in patients from the JCDTR database.2. Methods
2.1. Subjects
A total of 10,884 patients with cardiac implantable devices
that had been implanted from 2006 to 2010 were enrolled in thelsevier B.V. All rights reserved.
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reported [23]. The JCDTR questionnaires consisted of 3 parts,
including implantation information, patient characteristics, and
pharmacological treatment at the time of enrollment; the details
were described in a previous report [23].
In this study, 10,605 patients, including those with newly
implanted ICDs and CRT-Ds and upgraded devices from CRT-Ps to
CRT-Ds, were selected. We investigated the clinical aspects
of underlying heart disease in primary and secondary prevention of
sudden cardiac death, and the number and percentage of implanted
ICDs and CRT-Ds, including upgrades from CRT-Ps to CRT-Ds.
Patient diagnoses were determined according to the answers
of the JCDTR questionnaire. The underlying heart diseases were
divided into 12 categories: ischemic heart disease (IHD), dilated
cardiomyopathy (DCM), secondary cardiomyopathy (2nd CM),
arrhythmogenic right ventricular cardiomyopathy (ARVC), hyper-
tensive heart disease (HHD), valvular heart disease (VHD), con-
genital heart disease (CHD), hypertrophic cardiomyopathy (HCM),
Brugada syndrome (Brugada), long QT syndrome (LQT), idiopathic
VT/VF (IVF group, which excluded Brugada and LQT), and mis-
cellaneous (Mis.).
Furthermore, the 2nd CM patients were divided into 16 under-
lying disease groups: cardiac sarcoidosis, amyloid cardiomyopa-
thy, muscle dystrophy, (post) myocarditis, collagen disease, left
ventricular (LV) aneurysm, dilated-type HCM, LV compaction,
drug-induced cardiomyopathy, Takozubo cardiomyopathy, conge-
nital metabolic disease, hemodialysis, complete atrioventricular
(AV) block, tachycardia-induced cardiomyopathy, cardiac tumor,
and Mis.
In addition, the IVF group consisted of 8 categories: IVF,
catecholaminergic polymorphic VT, short-coupled polymorphic
VT, vasospastic angina, early repolarization syndrome, idiopathic
VT, familial IVF, and syncope of unknown etiology.
Regarding the clinical aspects, we studied the gender ratio
(male/female), left ventricular ejection fraction (LVEF), New York
Heart Association (NYHA) classiﬁcation, type of deﬁbrillator and
mode (ICD or CRT-D and single chamber or dual chamber), and
the incidence of atrial ﬁbrillation (AF), in all patients. Further-
more, we investigated the number of therapeutic interventions
for the primary and secondary prevention of underlying heart
disease, distribution of underlying heart diseases, changes in the
number of ICDs and CRT-Ds and the trends in the percentage of
primary prevention (% primary) from 2006 to 2010.Table 1
Age and gender distribution of patients with underlying heart disease.
Primary Secondary
n Mean7sd M/F n Mean7sd M/F
IHD 1196 68.879.9 7.4 2468 66.9710.5 5.8
DCM 1524 64.8712.5 2.7 1147 63.4712.5 2.9
2nd CM 354 61.5713.4 1.3 441 60.0713.2 1.3
ARVC 36 53.6716.5 1.1 160 57.4714.9 2.5
HHD 44 71.378.4 7.8 105 67.5710.5 3.4
VHD 132 69.478.6 4.1 202 66.9712.0 2.1
CHD 34 55.7718.7 2.1 81 52.6719.3 1.5
HCM 299 61.8712.8 1.9 596 61.1715.1 2.7
Brugada 403 50.3713.8 20.2 457 47.4714.1 23.1
IVF 42 53.8720.2 3.7 608 51.6716.3 3.4
LQT 12 45.2723.6 0.5 149 48.3721.8 0.4
Mis. 28 63.7716.9 6.0 87 61.8714.0 2.5
0.5
Total 4104 63.9713.4 3.5 6501 61.6714.6 3.4
M/F: the ratio of male to female, AF: atrial ﬁbrillation, IHD: ischemic heart disea
arrhythmogenic right ventricular cardiomyopathy, HHD: hypertensive heart disease,
cardiomyopathy, Brugada: Brugada syndrome, LQT: long QT syndrome, IVF: idiopathic
pri.: primary prevention, Secondary/sec.: secondary prevention, sd: standard deviation2.2. Statistical analysis
The values for the continuous variables are presented as the
mean7the standard deviation. The differences in the clinical
characteristics were tested by the chi-square test. Informed
consent for each examination was obtained at the individual
hospitals and facilities.3. Results
A total of 10,605 patients were included in our study, with
7016 ICDs (66.2%), 3518 CRT-Ds (33.2%), and 71 upgrade devices
from CRT-Ps to CRT-Ds (0.7%).1.Tot
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In general, the gender ratio (male/female) was greater than
1 for all underlying diseases, except LQT (0.4). A remarkable
difference in gender ratio was observed in patients with
Brugada (21.6) and IHD (6.3). The gender ratios for IHD and
VHD were signiﬁcantly higher in the primary prevention group
than in secondary prevention group, and vice versa for ARVC
and HCM. In the IHD primary prevention group, the NYHA
classiﬁcation was signiﬁcantly lower in males (2.370.9) than
in females (2.470.9), but the LVEF was not signiﬁcantly
different between males (36.5718.2%) and females (35.77
17.4%). In the IHD secondary prevention group, there were
signiﬁcant gender differences in both the NYHA classiﬁcations
(males 1.870.9 vs. females 1.970.9; po0.0001) and LVEF
(males 45.6717.8% vs. females 47.0718.1%; po0.0001).
The mean age of the patients was 62.5714.2 years, and ranged
from 10 to 95 years of age. Overall, the patients in the primary
prevention group were signiﬁcantly older (63.9713.4 years of
age; po0.0001) than the patients in the secondary prevention
group (61.6714.6 years of age). Patients with HHD, VHD, and
IHD were relatively older (mean age476 years of age), and
patients with LQT, Brugada, and IVF were relatively younger
(mean ageo52 years of age) relative to patients with the other
underlying diseases in this study.2. LVEF and NYHA classiﬁcation of patients with underlying heart
disease (Table 2)
In general, the LVEF of the primary prevention group
(36.3718.0%) was signiﬁcantly lower (po0.0001) than thatal
Mean7sd (min.max.) p. vs. s. M/F pri. vs. sec.
64 67.6710.3 16–95 0.0001 6.3 0.0213
71 64.2712.5 14–93 0.0193 2.8 0.3886
95 60.7713.3 12–89 0.2616 1.3 0.9029
96 56.7715.3 16–87 0.1578 2.1 0.0320
49 68.6710.0 38–88 0.0982 4.1 0.106
34 67.9710.8 18–90 0.0291 2.7 0.0123
15 53.5719.1 12–87 0.5089 1.7 0.4694
95 61.3714.4 11–91 0.4453 2.4 0.0219
60 48.8714.1 15–83 0.0025 21.6 0.6916
50 51.8716.6 12–92 0.5449 3.5 0.8683
61 48.1721.9 10–87 0.6869 0.4 0.6658
15 62.2714.7 13–92 0.7687 3.0 0.1257
05 62.5714.2 10–95 0.0001 3.4 0.6981
DCM: dilated cardiomyopathy, 2nd CM: secondary cardiomyopathy, ARVC:
: valvular heart disease, CHD: congenital heart disease, HCM: hypertrophic
ricular ﬁbrillation (excluding Brugada and LQT), Mis.: miscellaneous, Primary/
n.: minimum, max.: maximum.
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dence of NYHA class III and IV was higher in the primary
prevention group (53.4 and 8.2%, respectively) than those of
the secondary prevention group (23.3 and 5.7%, respectively).
The LVEF values of patients treated for the primary prevention
of DCM, IHD, 2nd CM, VHD, and HHD were signiﬁcantly lower
than those of the secondary prevention group. However, the
mean LVEF of patients with HCM, Brugada, IVF, and LQT was
higher than 63%. The mean LVEF of patients with DCM, IHD,
2nd CM, and VHD was lower than 40%. Interestingly, the DCM
group had the worst LVEF and contained the largest number of
NYHA class III and IV patients.3. Incidence of AF (Table 3)
The highest incidence of AF occurred in the VHD group (27.8%).
The Brugada,
LQT, IVF, and ARCV groups had relatively lower incidences,
which were less than 5%.4. Distribution of underlying heart disease (overall, primary, and
secondary prevention)
The major underlying diseases in this patient cohort included
IHD (35%), DCM (25%), 2nd CM (8%) and Brugada (8%). IHD and
DCM occurred in 60% of patients, and occurred in 66% of the
primary prevention group and 56% of the secondary preven-
tion group (Fig. 1). Note that the incidence of IHD (29%) was
lower than that of DCM (37%) in the primary prevention group,
but the opposite occurred in the secondary prevention group
(IHD: 38%, DCM: 18%).5. Type of deﬁbrillator and mode (Table 4)
In patients with ICDs, IHD was the most prevalent underlying
disease (36%), followed by DCM (12%), HCM (12%), Brugada
(12%), and IVF (9%) [Table 4, Fig. 2]. On the other hand, 50% of
CRT-Ds were implanted for the treatment of DCM, and 32%
were implanted for IHD treatment. Including patients with a
2nd DCM increased the incidence of DCM to 70% in patients
with CRT-Ds (Table 4C, Fig. 2).
In all patients (Table 3D), dual chamber devices were used in
80.1% and single chamber devices were used in 19.9%. The
underlying disease in which single chamber ICDs were most
frequently used was VHD (36.5%), followed by Brugada (34.8%)
and IVF (27.7%).6. Subclassiﬁcation of the underlying heart diseases
Subclassiﬁcation of the 2nd CM and IVF groups (Table 5): in
the 2nd CM group, cardiac sarcoidosis had the highest inci-
dence, and occurred in 45% of all patients, in 43.5% of the
primary prevention group, and in 46.3% of the secondary
prevention group (Table 5A). The second most prevalent
condition was DCM, with 22.5% incidence among all patients,
26.8% incidence in the primary prevention group, and 19.0%
occurrence in the secondary prevention group.
In the IVF group (Table 5B), IVF was the most prevalent
condition (n¼480; 73.8%), with a substantially higher inci-
dence in the secondary prevention group (n¼608; 93.5%) than
in the primary prevention group (n¼42; 6.5%). The second
most prevalent condition was idiopathic VT (n¼86; 13.2%),
and the third most prevalent condition was vasospastic angina
(n¼66; 10.2%).7. Changes in the rates of ICD and CRT-D utilization (Fig. 3)
The percentage of CRT-Ds used for primary prevention dra-
matically increased from 2006 (10.3%) to 2007 (22.1%) and
then gradually increased from 2007 to 2010; the opposite
occurred in the percentage of ICDs used for secondary preven-
tion. The percentage of CRT-Ds for secondary prevention and
ICDs for primary prevention did not change signiﬁcantly
during this time period.8. Trends in the % primary: Among the 4 major diseases, the DCM
group had the largest number of patients (n¼1524) and thehighest % primary (57.1%; Table 4). The second highest %
primary (46.9%) occurred in the Brugada group. The IHD group
had the fourth highest % primary (32.6%), but had the second
highest number of patients (n¼1196). Over the 5-year period,
the % primary values of the DCM and HCM group gradually
increased (Fig. 4, Table 4). The % primary of the IHD group also
gradually increased, but the ratio of this increase was smaller
compared with the DCM group. Conversely, the % primary of
the Brugada group gradually increased since 2006, and then
gradually decreased from 2008 to 2010 (Fig. 4). The % primary
for patients with DCM and implanted CRT-Ds dramatically
increased from 2006 (46.8%) to 2007 (67.5%), and then gradu-
ally increased until 2010 (73.1%). For patients with IHD and
implanted CRT-Ds, the % primary gradually increased from
2006 (57.8%) to 2010 (65.0%)
4. Discussion
The purpose of this study was to determine the current status
of deﬁbrillation therapy (ICD/CRT-D) in Japan by using the JCDTR
database administrated by the device enrollment and assessment
committee of the Japanese Heart Rhythm Society. Speciﬁcally, the
clinical aspects and trends in the % primary for sudden cardiac
death were emphasized, because the effectiveness of deﬁbrilla-
tion therapy for secondary prevention has been assessed and
conﬁrmed throughout the world [5,9]
4.1. Gender and age
In an analysis of a national sample of Medicare inpatient,
outpatient, and carrier standard analytical ﬁles and the corre-
sponding denominator ﬁles, women were found to be signiﬁ-
cantly less likely than men to receive ICD therapy for the primary
or secondary prevention of sudden cardiac death [26], which was
similar to the ﬁndings of this study.
In LQT, the gender ratio varies by age and abnormal gene type.
Women have slightly longer QT intervals than men do, and this
difference is more pronounced at slower heart rates [12]. In an
international study of 287 child patients, the gender ratio was 0.8
[27]. In a prospective longitudinal study of 328 families who were
mostly adults, the gender ratio of the probands was 3.8 [28].
In this study, the gender ratio of LQT was 0.4 in patients who
underwent secondary prevention therapy in Japan.
A remarkable difference in the gender ratios was observed in
the Brugada group, with a ratio of 21.6 in all patients, and 23.1 in
the secondary prevention group. These results are not inconsis-
tent with previous reports [16–19,29]; however, these reports
also revealed that the gender ratio in all patients ranges from 2.5
[19] to 3.2 [16] in western countries and is 21.0 in Japan [18]. Of
note, the gender ratio in symptomatic patients ranges from 5.0
[16] to 11.0 [17] in western countries and is 23.6 in Japan [18]. In
this study, the gender ratio was 23.1 in secondary prevention
patients and 20.2 in primary prevention patients; therefore, our
data were not inconsistent with previous Japanese data [18].
There were signiﬁcant differences in the gender ratios of
patients with IHD, ARVC, VHD, and HCM between the primary
and secondary prevention groups (Table 1). Those of the IHD and
VHD groups were signiﬁcantly higher in the primary prevention
group than in the secondary prevention group, and vice versa for
patients with ARVC and HCM. The clinical signiﬁcance of these
results remains unclear.
The mean age was 62.5714.2 years among all of the patients,
and ranged from 10 to 95 years of age. The patients with HHD,
VHD, and IHD were relatively older, and those with LQT, Brugada,
and IVF were relatively younger compared with patients with the
Table 2
LVEF and NYHA classiﬁcation of patients with underlying heart disease.
Primary Secondary Total
Mean7sd Mean7sd Mean7sd pri. vs. sec.
A. LVEF
IHD 31.3712.2 39.5714.6 36.9714.4 0.0001
DCM 26.279.4 31.3711.4 28.4710.6 0.0001
2nd CM 34.4714.0 40.3714.8 37.7714.7 0.0001
ARVC 53.1715.4 56.4713.4 55.8713.8 0.236
HHD 37.9718.2 51.3717.7 47.4718.8 0.0001
VHD 30.7712.1 43.2717.4 38.3716.7 0.0001
CHD 44.2717.7 46.7716.6 46.0716.9 0.335
HCM 63.1710.8 62.3711.8 62.6711.5 0.232
Brugada 66.577.2 66.477.1 66.477.2 0.837
IVF 62.679.7 63.478.8 63.478.8 0.486
LQT 62.478.9 63.4711.1 63.3710.9 0.789
Mis. 44.6718.4 55.9713.5 53.1715.5 0.0002
Total 36.3718.0 45.9717.9 42.2718.5 0.0001
Primary Secondary All
I II III IV total I II III IV total I II III IV Total pri. vs. sec.
B. NYH
IHD
n 149 361 600 86 1196 816 1069 470 113 2468 965 1430 1070 199 3664 o0.0001
% 12.5 30.2 50.2 7.2 100.0 33.1 43.3 19.0 4.6 100.0 26.3 39.0 29.2 5.4 100.0
DCM
n 80 376 909 159 1524 202 427 422 96 1147 282 803 1331 255 2671 o0.0001
% 5.2 24.7 59.6 10.4 100.0 17.6 37.2 36.8 8.4 100.0 10.6 30.1 49.8 9.5 100.0
2nd CM
n 73 107 159 15 354 158 167 89 27 441 231 274 248 42 795 o0.0001
% 20.6 30.2 44.9 4.2 100.0 35.8 37.9 20.2 6.1 100.0 29.1 34.5 31.2 5.3 100.0
ARVC
n 22 9 4 1 36 116 28 13 3 160 138 37 17 4 196 0.6070
% 61.1 25.0 11.1 2.8 100.0 72.5 17.5 8.1 1.9 100.0 70.4 18.9 8.7 2.0 100.0
HHD
n 10 16 15 3 44 51 39 13 2 105 61 55 28 5 149 0.0081
% 22.7 36.4 34.1 6.8 100.0 48.6 37.1 12.4 1.9 100.0 40.9 36.9 18.8 3.4 100.0
VHD
n 7 42 76 7 132 46 90 51 15 202 53 132 127 22 334 o0.0001
% 5.3 31.8 57.6 5.3 100.0 22.8 44.6 25.2 7.4 100.0 15.9 39.5 38.0 6.6 100.0
CHD
n 8 15 11 0 34 32 28 16 5 81 40 43 27 5 115 0.1087
% 23.5 44.1 32.4 0.0 100.0 39.5 34.6 19.8 6.2 100.0 34.8 37.4 23.5 4.3 100.0
Total
n 349 926 1774 271 3320 1421 1848 1074 261 4604 1770 2774 2848 532 7924 o0.0001
% 10.5 27.9 53.4 8.2 100.0 30.9 40.1 23.3 5.7 100.0 22.3 35.0 35.9 6.7 100.0
See Table 1 for abbreviation deﬁnitions.
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inconsistent with general concepts. Patients with IHD, DCM, and
Brugada that underwent primary prevention therapy were sig-
niﬁcantly older than those in the secondary prevention group.
These ﬁndings might be explained by the fact that deﬁbrillation
therapy was performed in spite of their age when patients had
lethal ventricular arrhythmias.
4.2. Distribution of underlying diseases (Figs. 1 and 2)
The major underlying diseases in patients with implanted ICDs
included IHD (36%), cardiomyopathy (19%; 12% with DCM plus 7%
with 2nd CM), HCM (12%), ARVC (3%) and the IVF group (21%; 12%
with Brugada plus 9% with IVF). A study published in 1998
regarding ICDs in Japan [25] included a patient cohort with IHD
(34%), DCM (16%), HCM (12%), ARVC (3%), an IVF group (19%), and
other underlying diseases (12%). Thus, the distribution of the
underlying heart diseases in this study was similar to the previous
report [25]. However, among all of the patients in the current
study, we found that the major underlying diseases included IHD
(35%), cardiomyopathy (33%; 25% with DCM plus 8% with 2ndTable 3
Incidence of atrial ﬁbrillation
n AF %
IHD 3664 363 9.9
DCM 2671 353 13.2
2nd CM 795 62 7.8
ARVC 196 5 2.6
HHD 149 30 20.1
VHD 334 93 27.8
CHD 115 18 15.7
HCM 895 133 14.9
Brugada 860 21 2.4
IVF 650 31 4.8
LQT 161 4 2.5
Mis. 115 63 54.8
Total 10605 1176 11.1
See Table 1 for abbreviation deﬁnitions.
Fig. 1. Distribution of the underlying heart diseases (among all patients, patients that
prevention therapy).
See Table 1 for abbreviation deﬁnitions.CM), HCM (8%), ARVC (2%) and the IVF group (14%; 8% with
Brugada plus 6% with IVF). Of note, the percentage of patients
with DCM in the current study was higher than that of the study
published in 1998 [25]. This difference may be explained by the
increase in prophylactic therapy, especially the utilization of
CRT-Ds in patients with cardiomyopathy.
This distribution of the underlying heart diseases in Japan was
absolutely different compared with that of western countries. In
the USA, IHD was reported in 80% of registry patients, cardiomyo-
pathy in 10%, and IVF in 3% [25]. Another registry report from
Italy [10] during the period from 2001 to 2004 revealed that the
68.1% of patients had IHD. Over the same period, DCM was
reported in 23.2% of all cases, HCM in 3.3%, ARVC in 1.5%, VHD
in 1.7%, LQT in 0.7%, and IVF in 1.5% of patients [10].4.3. Primary and secondary prevention
There were 82% primary and 18% secondary prevention indica-
tions in the ICD therapy registry collected from December 2004 to
April 2005 in the United States, compared with 42% primary and
58% secondary prevention indications in the Italian ICD registry
collected from January to December 2005 (po0.0001) [11]. In a
comparison of the 2006–2010 data for ICD and CRT-D use in this
study, there was a signiﬁcantly (po0.0001) lower primary pre-
vention rate (38.7%) in Japan than that in Italy in 2005 [11].
In western countries, the distribution of underlying heart
diseases in patients treated with ICDs for primary prevention is
very similar to that of all ICD recipients [10], indicating that there
is not much difference in the distribution of underlying heart
diseases between primary and secondary prevention patients.
However, differences in the distribution of diseases between
primary and secondary prevention patients were observed in
the current study, especially in patients with DCM and IVF
(Fig. 1). In the DCM group, the percentage changed from 18% in
the secondary prevention group to 37% in the primary prevention
group, and the opposite trend was observed in patients with
IVF (9–1%). The DCM group had the largest number of patients
and the highest % primary (57.1%), and no other disease wasunderwent primary prevention therapy, and patients that underwent secondary
Table 4
Type and mode of deﬁbrillation device in patients with underlying heart disease by year
2006 2007 2008 2009 2010 2006–2010
Pri. Sec. Pri. Sec. Pri. Sec. Pri. Sec. Pri. Sec. Pri. % Sec. % Total %
A. ICDþCRT-D
IHD 137 405 223 488 275 557 304 560 257 458 1196 32.6 2468 67.4 3664 100.0
DCM 122 209 321 259 362 252 348 235 371 192 1524 57.1 1147 42.9 2671 100.0
2nd CM 46 86 72 96 70 82 80 108 86 69 354 44.5 441 55.5 795 100.0
ARVC 9 33 6 35 6 38 8 24 7 30 36 18.4 160 81.6 196 100.0
HHD 8 15 4 22 4 21 11 19 17 28 44 29.5 105 70.5 149 100.0
VHD 14 34 31 40 31 45 25 52 31 31 132 39.5 202 60.5 334 100.0
CHD 4 12 4 11 7 25 10 15 9 18 34 29.6 81 70.4 115 100.0
HCM 44 102 65 151 65 123 73 126 52 94 299 33.4 596 66.6 895 100.0
Brugada 72 79 103 104 89 89 71 88 68 97 403 46.9 457 53.1 860 100.0
IVF 12 85 7 115 13 131 7 146 3 131 42 6.5 608 93.5 650 100.0
LQT 0 20 5 31 4 32 1 39 2 27 12 7.5 149 92.5 161 100.0
Mis. 0 12 6 20 7 23 7 19 8 13 28 24.3 87 75.7 115 100.0
Total 468 1092 847 1372 933 1418 945 1431 911 1188 4104 38.7 6501 61.3 10605 100.0
B. ICD
IHD 85 367 79 387 100 458 126 449 105 376 495 19.5 2037 80.5 2532 100.0
DCM 49 126 55 131 68 121 71 117 55 76 298 34.3 571 65.7 869 100.0
2nd CM 20 70 28 59 36 49 28 85 35 48 147 32.1 311 67.9 458 100.0
ARVC 9 31 4 33 6 36 8 20 7 29 34 18.6 149 81.4 183 100.0
HHD 6 12 3 18 2 15 3 13 6 27 20 19.0 85 81.0 105 100.0
VHD 6 24 7 29 6 32 3 33 4 25 26 15.4 143 84.6 169 100.0
CHD 4 11 4 11 2 14 7 11 6 13 23 27.7 60 72.3 83 100.0
HCM 44 98 60 147 62 118 68 123 51 90 285 33.1 576 66.9 861 100.0
Brugada 72 79 102 104 89 89 71 87 68 97 402 46.9 456 53.1 858 100.0
IVF 12 85 7 115 13 131 7 144 3 129 42 6.5 604 93.5 646 100.0
LQT 0 20 5 29 4 32 1 38 2 26 12 7.6 145 92.4 157 100.0
Mis. 0 11 2 20 5 17 5 18 5 12 17 17.9 78 82.1 95 100.0
Total 307 934 356 1083 393 1112 398 1138 347 948 1801 25.7 5215 74.3 7016 100.0
C. CRT-D
IHD 52 38 144 101 175 99 178 111 152 82 701 61.9 431 38.1 1132 100.0
DCM 73 83 266 128 294 131 277 118 316 116 1226 68.0 576 32.0 1802 100.0
2nd CM 26 16 44 37 34 33 52 23 51 21 207 61.4 130 38.6 337 100.0
ARVC 0 2 2 2 0 2 0 4 0 1 2 15.4 11 84.6 13 100.0
HHD 2 3 1 4 2 6 8 6 11 1 24 54.5 20 45.5 44 100.0
VHD 8 10 24 11 25 13 22 19 27 6 106 64.2 59 35.8 165 100.0
CHD 0 1 0 0 5 11 3 4 3 5 11 34.4 21 65.6 32 100.0
HCM 0 4 5 4 3 5 5 3 1 4 14 41.2 20 58.8 34 100.0
Brugada 0 1 1 0 0 0 0 1 0 0 1 50.0 1 50.0 2 100.0
IVF 0 0 0 0 0 0 0 2 0 2 0 0.0 4 100.0 4 100.0
LQT 0 0 0 2 0 0 0 1 0 1 0 0.0 4 100.0 4 100.0
Mis. 0 0 4 0 2 6 2 1 3 1 11 55.0 9 45.0 20 100.0
Total 161 158 491 289 540 306 547 293 564 240 2303 64.2 1286 35.8 3589 100.0
Fig. 2. Distribution of the underlying heart diseases (according to the type of deﬁbrillator).
See Table 1 for abbreviation deﬁnitions.
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Table 5
Mode of deﬁbrillation device in patients with underlying heart disease by year
2006 2007 2008 2009 2010 2006–2010
Dual Single Dual Single Dual Single Dual Single Dual Single Dual % Single % Total %
IHD 458 84 534 177 699 133 789 75 632 83 3112 84.9 552 15.1 3664 100.0
DCM 220 111 347 233 462 152 509 74 497 66 2035 76.2 636 23.8 2671 100.0
2nd CM 108 24 127 41 130 22 177 11 138 17 680 85.5 115 14.5 795 100.0
ARVC 36 6 35 6 40 4 29 3 32 5 172 87.8 24 12.2 196 100.0
HHD 19 4 18 8 23 2 26 4 40 5 126 84.6 23 15.4 149 100.0
VHD 27 21 38 33 57 19 50 27 40 22 212 63.5 122 36.5 334 100.0
CHD 14 2 14 1 26 6 19 6 21 6 94 81.7 21 18.3 115 100.0
HCM 136 10 191 25 171 17 180 19 130 16 808 90.3 87 9.7 895 100.0
Brugada 109 42 127 80 118 60 107 52 100 65 561 65.2 299 34.8 860 100.0
IVF 77 20 75 47 104 40 118 35 96 38 470 72.3 180 27.7 650 100.0
LQT 19 1 29 7 26 10 35 5 26 3 135 83.9 26 16.1 161 100.0
Mis. 11 1 16 10 21 9 23 3 17 4 88 76.5 27 23.5 115 100.0
Total 1234 326 1551 668 1877 474 2062 314 1769 330 8493 80.1 2112 19.9 10605 100.0
See Table 1 for abbreviation deﬁnitions.
Fig. 3. Changes in the rates of ICD and CRT-D utilization for primary and
secondary prevention.
See Table 1 for abbreviation deﬁnitions.
Fig. 4. Trends in the percentage of primary prevention (% primary) in patients
with IHD, DCM, HCM, and Brugada.
See Table 1 for abbreviation deﬁnitions.
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IHD (32.6%) was not particularly high, and was the fourth highest
among the individual underlying diseases; however, this group
had the second highest number of patients in the primary
prevention category, since the IHD group included the highest
number of patients with deﬁbrillation therapy.
The reason for the relatively lower % primary in patients with
IHD compared with those of western countries is unclear, although
these differences are likely due to the population differences in the
IHD. Furthermore, Japanese physicians tend to believe that Japanese
patients have a lower risk of IHD and decreased LVEF than those ofwestern countries [24]. Indeed, Japanese patients who had received
intracoronary thrombosis or an emergent and/or elective percuta-
neous transluminal coronary angioplasty, had a favorable prognosis
[30]. Furthermore, the presence of non-sustained VT was a signiﬁ-
cant predictor of death (p¼0.036) only in the patients who did not
receive acute reperfusion, and the percentage of patients with
LVEFo35% was only 5.7% at 1378 days after myocardial infarction
[31]. There is a low incidence of sudden cardiac death in survivors of
myocardial infarction in the primary percutaneous coronary inter-
vention era, although LVEF is a predictor of increased risk for SCD
[32]. Tanno et al. [33] suggested that it might be inappropriate to
apply Multicenter Automatic Deﬁbrillator Implantation Trial II [2]
(MADIT II) criteria to Japanese patients, because the survival rate in
their study was comparable with that in the MADIT II [2] deﬁbril-
lator group. They also stated that a signiﬁcantly greater percentage
of the recently studied patients were found to be in NYHA class I and
that they had undergone more percutaneous coronary intervention
procedures than those enrolled in MADIT II [2].
The evaluation of deﬁbrillation therapy strategies becomes
difﬁcult when the primary prevention rate is much smaller in
patients with structural heart disease. In western countries, the
number of implanted devices for primary prevention has already
been reported to be larger than that for secondary prevention of
sudden cardiac death [11].
4.4. Single chamber vs. dual chamber devices
Among all of the deﬁbrillator devices in this study, single chamber
devices comprised 19.9%, which was signiﬁcantly smaller compared
with that of western countries, with 45.9% in the USA and 50.7% in
Italy [11]. The diseases that were more commonly treated with single
chamber devices were VHD (36.5%), Brugada (34.8%), and IVF (27.7%).
An explanation for the relatively higher incidence of VHD that was
treated with single chamber devices might be a high incidence of AF,
as the highest percentage of AF was observed in patients with VHD in
this study. With regard to the number of single chamber ICDs that
were used in Brugada, single chamber ICDs are preferred for primary
prevention in western countries [11,17,19]. The rationale for this
preference is that minimizing the exposure to lead will result in fewer
lead-associated problems.
4.5. Distribution of 2nd CM
In patients with 2nd CM, cardiac sarcoidosis was the most
commonly associated disease in this study. This disease was
invasive in only 2% of hearts; [34] although this is rare in systemic
A. Shimizu et al. / Journal of Arrhythmia 28 (2012) 263–272270sarcoidosis, it can occur suddenly. Furthermore, the initial phase of
sarcoidosis had a relatively high incidence of sudden cardiac death.
Therefore, the deﬁbrillation devices in patients with sarcoidosis
had a tendency to be implanted in the early phase of this disease
[34]. The second most commonly associated disease in patients
with 2nd CM was dilated-type HCM in this study, which is
associated with a poor prognosis and a tendency to cause lethal
congestive heart failure and/or lethal ventricular arrhythmia [35].
4.6. Distribution of the IVF group
Patients in the IVF group had no apparent heart disease, and
IVF was the most common diagnosis (73.8%) in the IVF group. The
purpose of ICD implantation in these patients was almost entirely
secondary prevention (95%), which can be expected due to the
clinical characteristics of IVF.
The second most common underlying disease in patients with
IVF in this study was idiopathic VT (13.2%), which was a bit
surprising since this disease is classiﬁed as indication class III,
according to the 2006 JCS guidelines [21]. However, VT is capable
of inducing syncope, dizziness, or heart failure, and the ﬁnal
decision regarding device implantation depends on discussions
between the doctors and patients. The third most common under-
lying disease in the IVF group was vasospastic angina (n¼66;
10.2%), for which the indication of deﬁbrillation therapy was
classiﬁed as indication III according to the 2006 JCS guidelines
[21]. However, the indication class of this disease is still con-
troversial [36]. The newest 2011 JCS guidelines [22] suggest that
this disease should be moved to class IIb from class III. However,
further studies are necessary to determine the appropriate
patients in which implanted device therapy should be performed.
4.7. Changes in the rates of ICD and CRT-D utilization
The percentage of CRT-Ds that were used for primary prevention
increased gradually according to this study, which is not incon-
sistent with the data reported by the Japanese device association
[22]. Furthermore, similar phenomena have occurred in western
countries [10]. There are several possible explanations as to why the
percentage of CRT-D implantation for primary prevention increased
rapidly, with the ﬁrst being that CRT-Ds were approved by the
Japanese Ministry of Health, Labor, and Welfare in August 2006.
Other possible explanations are the new guidelines for ICD implan-
tation, the favorable results of mega-trials [7,8,37,38], the progres-
sive technological advances in devices, and the cooperation between
cardiologists in the heart failure clinics and electrophysiology
laboratories of Japanese hospitals.
Though non-sustained VT and inducible VT/VF are major risk
factors for patients with severe LV function [1], ICDs reduce the
number of sudden cardiac deaths in patients with or without non-
sustained VT and/or inducible VT/VF [2]. Also, the 2006 JCS
guidelines [21] state that the indication of device implantation
in patients with severe LV dysfunction (LVEFr35%) is classiﬁed
as class IIa, regardless of the presence of ventricular arrhythmia.
In the patients with a LVEFr35%, drug resistant congestive heart
failure (NYHA class III/IV), intraventricular conduction distur-
bance (a QRS complex with a width of 130 ms or more), and
with or without a history of fatal ventricular arrhythmias, the
implantation of CRT-P or CRT-D were classiﬁed as a class I
indication. After these guidelines were published, prophylactic
deﬁbrillation therapy, especially CRT-D, dramatically increased.
4.8. Trends in the % primary
During the 5-year period in the current study, the JCDTR has
demonstrated a signiﬁcant increase in the utilization of prophylacticdeﬁbrillation devices (ICD/CRT-D). Interestingly, the % primary
values in patients with DCM and HCM gradually increased from
2006 to 2010. The % primary in patients with IHD also gradually
increased, but the ratio of this increase was smaller compared to
that of the DCM group (Fig. 4). These ﬁndings reﬂect the rapid
clinical implementation of the results of randomized studies [3,4,7].
With regard to patients with HCM, appropriate ICD interven-
tions were analyzed with respect to previously identiﬁed HCM
risk factors [13–15]. The 5 primary prevention risk factors were:
(1) history of premature HCM-related sudden death in 1 or more
ﬁrst-degree or other relatives that were younger than 50 years of
age, (2) massive LV hypertrophy (a maximum wall thickness of
30 mm or more), (3) 1 or more runs of non-sustained VT at heart
rates of 120 beats/min or greater while under 24-h ambulatory
Holter electrocardiographic monitoring, (4) prior unexplained
syncope judged to be inconsistent with a neurocardiogenic origin,
and (5) hypotensive blood pressure response to exercise [15]. In
most reliable data registry of 506 HCM patients from 42 centers
[13], discharge rates were 5.5%/year overall, 11%/year for second-
ary prevention (after cardiac arrest or sustained VT), and 4%/year
for primary prevention (with 1 or more risk factors). Therefore, a
single marker of high risk for sudden death may be sufﬁcient to
justify prophylactic deﬁbrillator implantation in selected patients
with HCM [13]. These statements most likely increased the
prophylactic ICD implantation rates in patients with HCM in
Japan. Furthermore, a new 2011 JCS guideline [22] is associated
with this statement.
Conversely, the % primary in patients with Brugada gradually
increased at ﬁrst, then gradually decreased from 2008 to 2010 in
this study. This phenomenon might be explained as follows. In
2003, Brugada et al. [16] indicated that patients with induced VF
during the electrophysiologic stimulation test (EPS) had a mod-
erately high risk even if they were asymptomatic. However, the
mega-trial conducted by Ecardt in 2005 [17], which was opened
to Japanese patients in 2009 [18], and results from the France,
Italy, Netherlands, Germany (FINGER) registry [19] reported in
2010, stated that clinicians should be prudent in implanting ICDs
in patients with asymptomatic Brugada, even if VF was induced
during electrophysiologic stimulation test. According to the 2007
JCS guidelines for Brugada and LQT syndrome [39], the history of
syncope due to an undetermined cause, family history of sudden
cardiac death, and inducible VF are risk factors for sudden cardiac
death in asymptomatic Brugada. The indication of device implan-
tation is class IIa when patients have 2 or more risk factors, and it
is a class IIb indication when patients have only 1 risk factor. We
have no data as to whether this statement is accurate; however, a
2011 report from Italy [40] supported the 2007 JCS Brugada
guidelines [39]. The authors of the Italian study selected the 3 risk
factors (syncope, family history of sudden cardiac death, and
positive EPS) in patients with asymptomatic type 1 Brugada,
which were the same as those described in the 2007 JCS guide-
lines. The follow-up data from this study indicated that subjects
with the highest risk of sudden cardiac death have at least 2 risk
factors, and that the remaining subjects have a low risk [40]. The
annual event rate in patients with asymptomatic Brugada was
0.5% [18], and the indication for device implantation was carefully
considered because of the relatively low risk, the poor cost-
effectiveness, and the reduction of quality of life (QOL). This
evidence seemed to inﬂuence the physician’s decision regarding
the indication of ICD use in patients with Brugada.
4.9. Study limitations
The JCDTR database collects clinical and technical data of
patients treated with ICDs and CRT-Ds. It is the largest such
database, consisting of more than 10,000 patients with implanted
Table 6
Distribution of 2nd CM and idiopathic ventriculartachycardia/ﬁbrillation with the exception of Brugada syndrome
Primary Secondary Total
n % n % n %
A. 2nd CM
Cardiac sarcoidosis 154 43.5 204 46.3 358 45.0
Amyloid cardiomyopathy 31 8.8 15 3.4 46 5.8
Muscular dystrophy 18 5.1 18 4.1 36 4.5
(Post) myocarditis 11 3.1 34 7.7 45 5.7
Collagen disease 2 0.6 9 2.0 11 1.4
Left ventricular aneurysm 5 1.4 17 3.9 22 2.8
Dilated-type HCM 95 26.8 84 19.0 179 22.5
Left ventricular compaction 10 2.8 13 2.9 23 2.9
Drug-induced 6 1.7 6 1.4 12 1.5
Takozubo cardiomyopathy 1 0.3 7 1.6 8 1.0
Congenital metabolic disease 3 0.8 6 1.4 9 1.1
Hemodialysis 2 0.6 5 1.1 7 0.9
Complete AV block 3 0.8 13 2.9 16 2.0
Tachycardia-induced 7 2.0 0 0.0 7 0.9
Cardiac tumor 1 0.3 4 0.9 5 0.6
Mis. 5 1.4 6 1.4 11 1.4
Total 354 100.0 441 100.0 795 100.0
B. Distribution of idiopathic ventricular tachycardia/ﬁbrillation with the exception of Brugada syndrome and long QT syndrome
Idiopathic ventricular ﬁbrillation 24 57.1 456 75.0 480 73.8
Catecholaminergic polymorphic ventricular tachycardia 1 2.4 4 0.7 5 0.8
Short-coupled polymorphic ventricular tachycardia 0 0.0 2 0.3 2 0.3
Vasospastic angina 4 9.5 62 10.2 66 10.2
Early repolarization syndrome 1 2.4 1 0.2 2 0.3
Idiopathic ventricular tachycardia 11 26.2 75 12.3 86 13.2
Family of idiopathic ventricular ﬁbrillation 1 2.4 0 0.0 1 0.2
Syncope of unknown etiology 0 0.0 8 1.3 8 1.2
Total 42 100.0 608 100.0 650 100.0
See Table 1 for abbreviation deﬁnitions.
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made in each hospital or by faculty in this study, the details of the
diagnoses were not organized. Although the number of registries
did not run parallel to the real number of implanted devices, the
changes observed in the percentage of ICD or CRT-D use over the
5-year period was similar to the previous report on this matter.
Therefore, we believe that the data in the present study reﬂects
the real world scenario of implantation deﬁbrillation devices.4.10. Conclusions
The JCDTR database revealed that the major underlying dis-
eases in patients that underwent deﬁbrillator therapy were ICD,
DCM, HCM, and Brugada in Japan. The distribution of diseases
that were treated with ICDs in this study was similar to that
reported in a study in 1998 [25]. The % primary was relatively
higher in patients with DCM and Brugada. Recent evidence
(mega-trial reports) and guidelines have inﬂuenced the indication
of primary prevention for sudden cardiac death in patients,
especially those with DCM in Japan. Such evidence has also
inﬂuenced this indication in patients with IHD, but this group
had a relatively lower % primary, despite its large number of
patients.
Decisions regarding deﬁbrillation therapy become difﬁcult
when the primary prevention rate is much smaller in patients
with structural heart disease. Importantly, a long-term observa-
tion study is needed to determine whether the current status of
deﬁbrillation therapy in Japan is heading in the right direction for
patients (Table 6).Appendix
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